Looking at the tumor grading, we found an increased mean of HER2+ DTCs in patients with grade 3 (n = 28) vs. grade 2 (n = 15) tumors (mean 0.6 vs. 0.3) and increased mesenchymal DTCs (CK-Vim+) in grade 3 vs. 2 (mean 1.1 vs. 0.6) along with increased CK- cells (mean 1.7 vs. 1.1) in cases with grade 3 vs. grade 2 tumors. The gene discussed is ERBB2; the disease is neoplasm.